Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04419623 · ClinicalTrials.gov registry record · Phase 1
A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer
A Phase 1 study, sponsored by Telios Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT04419623 is a Phase 1 study that has completed, run by Telios Pharma. The registered enrollment target is 7 participants.
The verdict
NCT04419623, a Phase 1 study, has completed, sponsored by Telios Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
This study evaluates TL-895, a tyrosine kinase inhibitor (TKI). This is a study comprising a Phase 1 safety assessment. TL-895 open-label will be administered orally at an assigned dose continuously in 7-day cycles for 2 cycles. Up to 3 dose levels will be evaluated. Only Phase 1 of the study was enrolled and the study did not proceed into Phase 2.
Interventions
- DRUG TL-895
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2020-07-09 |
| Est. Completion | 2020-12-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04419623
The ClinicalTrials.gov registry entry for NCT04419623 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Telios Pharma, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TL-895 is the first listed.
NCT04419623 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04419623 about?
NCT04419623 is a clinical study titled "A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer". This study evaluates TL-895, a tyrosine kinase inhibitor (TKI). This is a study comprising a Phase 1 safety assessment. TL-895 open-label will be administered orally at an assigned dose continuously in 7-day cycles for 2 cycles. Up to 3 dose levels will be evaluated. Only Phase 1 of the study was e...
What is the current status of trial NCT04419623?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2020-07-09. Estimated completion is 2020-12-15.
What interventions are being tested in trial NCT04419623?
The interventions under investigation include: TL-895 (DRUG).
Who is sponsoring clinical trial NCT04419623?
This trial is sponsored by Telios Pharma, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.